Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan

doi:10.1007/s11060-006-9241-y

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

J Neurooncol. 2007 Mar;82(1):81-3. doi: 10.1007/s11060-006-9241-y. Epub 2006 Aug 31.

Authors

Marc C Chamberlain¹, Michael J Glantz, Lisa Chalmers, Alixis Van Horn, Andrew E Sloan

Affiliation

¹ Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-0804, USA. ChambeMC@moffitt.usf.edu

PMID: 16944309
DOI: 10.1007/s11060-006-9241-y

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antineoplastic Agents, Alkylating / administration & dosage*
Brain Neoplasms / drug therapy
Brain Neoplasms / pathology
Brain Neoplasms / radiotherapy*
Chemotherapy, Adjuvant
Combined Modality Therapy
Dacarbazine / administration & dosage
Dacarbazine / analogs & derivatives*
Female
Glioblastoma / drug therapy
Glioblastoma / pathology
Glioblastoma / radiotherapy*
Humans
Male
Middle Aged
Necrosis
Radiation-Sensitizing Agents / administration & dosage*
Radiotherapy Dosage
Temozolomide
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Radiation-Sensitizing Agents
Dacarbazine
Temozolomide